



FOR IMMEDIATE RELEASE

Medical Diagnostic Laboratories, L.L.C. Announces a New *BRCA1* and *BRCA2* Mutation Test – *BRCACare*.

Hamilton, NJ., January, 2015 - Medical Diagnostic Laboratories, L.L.C., (MDL), is a CLIA-certified laboratory which specializes in state-of-the-art, high complexity, automated DNA-based molecular analyses is announcing that it is offering a *BRCA1* and *BRCA2* mutation test, *BRCACare*, for hereditary breast and ovarian cancer syndrome (HBOC).

Breast cancer is the second most common newly diagnosed cancer and second leading cause of cancer death among women in the United States. In 2014, the American Cancer Society's estimated about 232,670 new cases of invasive breast cancer in women. Specific inherited mutations in *BRCA1* and *BRCA2* genes have been associated with increased risks of breast and ovarian cancer. For women who have mutations in *BRCA1* and/or *BRCA2* genes, the life time risk can reach up to 50-85% for breast cancer and 10-40% for ovarian cancer by the age of 70.

Utilizing a cutting edge technology, including the next generation sequencing platforms, MDL offers a diverse panel of breast cancer testing, including the Comprehensive *BRCA* Analysis, Ashkenazi Jewish 3-site Mutation Panel and Single Site Mutations Analysis. Results of the *BRCACare* test provide individualized medical management for the high-risk population. Our innovative genetic testing assists in risk assessment, prevention, diagnosis and treatment of cancer in *BRCA* mutation carriers. The results obtained from the *BRCACare* test allows patients to make proactive decisions regarding risk-reducing surgical treatment, preventive chemotherapy or fertility preservation, while also giving family members the ability to avoid unnecessary testing. Performing enhanced screening for *BRCA1* and *BRCA2* mutation carriers and family members significantly improves medical outcomes (cancer surveillance and mortality), and reduce medical costs through early diagnosis and early treatment.

The Institute for Biomarker Research, a Division of MDL, was established to develop, validate and commercialize the innovative diagnostic assay for clinical practice. MDL is a member of the Genesis Biotechnology Group located in Hamilton, New Jersey in "Einstein's Alley", the research and technology corridor of New Jersey, in close proximity to major metropolitan centers in New York, New Jersey and Pennsylvania.

To learn more about this test and other MDL testing, please visit www.mdlab.com

Contact: **Martin Adelson**, Ph.D.

madelson@mdlabor.com

609.570.1015